By Fineline Cube 
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB 2.498 billion (USD 362 million) in total revenue, up 28.32% year-on-year, with drug sales surging 40.32% to RMB 2.301 billion. The net loss narrowed 31.68% to RMB 875 million as the company maintained RMB 1.342 billion in R&D investment across 90+ clinical studies. Core product toripalimab (Tuoyi) generated RMB 2.068 billion (up 38% YOY) with all 12 indications NRDL-listed, while new pipeline assets including subcutaneous toripalimab, roconkibart (IL-17A), and multiple Phase III programs position Junshi for sustained growth and profitability inflection.
Financial Performance Summary
| Metric | 2025 Result | Change (YOY) | Strategic Note |
|---|---|---|---|
| Total Revenue | RMB 2.498 bn (USD 362 mn) | +28.32% | Strong commercial momentum |
| Drug Sales Revenue | RMB 2.301 bn (USD 333 mn) | +40.32% | Core driver of growth |
| Net Loss (Parent) | RMB 875 mn (USD 127 mn) | -31.68% (narrowed) | Path to profitability improving |
| R&D Investment | RMB 1.342 bn (USD 194 mn) | Sustained | 90+ clinical studies ongoing |
| Overseas Revenue | Significant growth | Expanding | Toripalimab approved in 40+ countries |
Core Product Performance
| Product | 2025 Sales | Growth (YOY) | Strategic Highlights |
|---|---|---|---|
| Toripalimab (Tuoyi) | RMB 2.068 bn (USD 299 mn) | +38% | • PD-1 mAb core franchise • 12 approved indications (all NRDL-listed) • Approved in 40+ countries overseas • Subcutaneous formulation in marketing application |
| Junshida (ongericimab) | New launch | — | • PCSK9 mAb • First-time NRDL inclusion • Two indications approved |
Pipeline Advancement
| Asset | Class | Indication/Status | Strategic Value |
|---|---|---|---|
| Subcutaneous toripalimab | PD-1 mAb (new formulation) | Marketing application stage | Convenience upgrade; potential market expansion |
| Roconkibart | Anti-IL-17A mAb | Marketing application stage | Autoimmune diversification; psoriasis/ankylosing spondylitis |
| JS107 | CLDN18.2 ADC | Phase III | Gastric cancer; next-gen oncology asset |
| JS207 | PD-1/VEGF bispecific | China/U.S. IND approved | Dual mechanism; potential best-in-class |
| JS212 | EGFR/HER3 ADC | China/U.S. IND approved | Targeted therapy for solid tumors |
| JS213 | PD-1/IL-2 fusion | China/U.S. IND approved | Immune activation enhancement |
Strategic Context & Market Position
| Factor | Implication |
|---|---|
| NRDL Leverage | 100% toripalimab indication coverage ensures broad access; ongericimab NRDL inclusion drives rapid uptake |
| Global Expansion | 40+ country approvals for toripalimab validate international quality standards; emerging market revenue diversification |
| Formulation Innovation | Subcutaneous PD-1 addresses patient convenience; biosimilar defense strategy |
| Pipeline Depth | 90+ studies across oncology and immunology; multiple Phase III assets de-risk revenue concentration |
| Profitability Trajectory | Loss narrowing + 40% drug sales growth suggests break-even potential 2027-2028 |
Competitive Landscape
| Competitor | Key Product | China Position | Junshi Differentiation |
|---|---|---|---|
| BeiGene | Tislelizumab | Leading PD-1 | Toripalimab global approvals; formulation diversity |
| Hengrui | Camrelizumab | Large oncology portfolio | Junshi focus on quality/global expansion vs. volume |
| Innovent | Sintilimab | NRDL price leader | Toripalimab 40+ country approvals; international revenue |
| Junshi | Toripalimab + pipeline | 12 NRDL indications; 40+ global approvals | First-mover subcutaneous PD-1; diversified autoimmune (IL-17A) |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding profitability trajectory, pipeline advancement, and global expansion for Junshi Biosciences. Actual results may differ due to NRDL pricing pressures, competitive dynamics in PD-1/IL-17A markets, and clinical trial outcomes.-Fineline Info & Tech